CE VIDEO - The Seven Habits of Highly Effective Anterior Uveitis Management
Speaker:
Paul Karpecki, OD
Release Date:
January 20, 2021
Expiration Date:
December 27, 2023
Estimated time to complete activity:
1 hour
Computer System Requirements:
Access to internet and a web browser is required to complete this activity.
Goal Statement:
This lecture provides the key steps in optimal management of anterior uveitis or iridocyclitis.
Educational Objectives:
After completing this activity, the participant should be better able to:
- Recognize of the importance of a structured uveitis management protocol
- Discuss the ‘Seven Rules’ of iritis management to allow a clinician to better manage anterior uveitis and avoid complications
- Describe the importance of systemic disease associated with uveitis
- Review new therapeutics and how they are best used in the management of noninfectious anterior uveitis
Target Audience:
This activity is intended for optometrists who provide primary care optometry services, including but not limited to medical optometric services.
Faculty/Editorial Board:
Paul Karpecki, OD
Continuing Education Credit:
This activity, COPE Activity Number 120874 is accredited by COPE for continuing education for optometrists. This course is COPE approved for 1 hour of CE credit. Course ID is 70533-AS. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure.
Reviewed by :
Disclosure of Conflicts of Interest:
Review Education Group (REG) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to REG policy. REG is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Paul Karpecki, OD, FAAO
Consulting fees from Akorn, Alcon Labs, Aldeyra, Allergan/Abbvie, Azura Pharmaceuticals, Bausch & Lomb, BioTissue, BlephEx, Bruder Healthcare, Bruno Pharmaceuticals, Cambium Pharmaceuticals, Dompe, Eyedaptic, Eyedetec, Eyegate, Eyevance, Gobiquity, Healthe, Hubble, iCare, Imprimis, Ivantis, Jobson/WebMD, Johnson & Johnson Vision, Kala Pharmaceuticals, KEPLR Vision, Konan Medical, LeGrande, LenTechs, Maculogix, Mallinckrodt, Mitotech, Neurolens, Novartis, Oasis Medical, Ocuphire, Ocular Sciences, Oculus, OcuMedic, Omega Ophthalmics, Orasis, Osmotica, Oyster Point, RegenerEyes, Reichert, Rendia, RxSight, Science Based Health, Sentiss Pharmaceuticals, Sight Sciences, Silk Technologies, Sun Pharmaceuticals, Surface Pharmaceuticals, Tarsus Medical, TearClear, Visant Medical, Visus, Vital Tears
Contracted research with Ocuphire, Kala, Sight Sciences, Surface Pharmaceuticals, Bruno Pharmaceuticals
Fees for Non-CME/CE Services from Bausch & Lomb, Dompe, Eyevance, Kala, Mallinckrodt, Neurolens, Osmotica, Sun Pharmaceuticals
Royalties from EyeTherapies
Ownership interest in Allergan/Abbvie, Bausch & Lomb, BlephEx, Bruder Healthcare, Cambium Eyedaptic, Eyedetec, Gobiquity, Healthe, Ivantis, Kala, KEPLR Vision, LeGrande, LenTechs, Mati Therapeutics, Mitotech, Neurolens, Ocuphire, Ocular Sciences, OcuMedic, Omega Ophthalmics, Orasis, Oyster Point, RegenerEyes, RxSight, Science, Sight Sciences, Silk Technologies, Tarsus Medical, TearClear, Visant Medical, Bruder Healthcare
Method of Participation Request for Credit:
During the period January 20, 2021 through December 27, 2023 participants must read the learning objectives, faculty disclosures and view the complete educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation at the conclusion of this course. Post course tests must receive a score of 70% or better in order for a certificate of completion to be issued.
Media:
Video
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
